ReviewFrontiers in oncology2026
Hepatitis B virus, alcohol, and liver cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis is an infection caused by hepatotropic viruses that leads to liver inflammation and may progress from a prolonged asymptomatic phase to decompensated liver disease. Among the main types, hepatitis A (HAV), B (HBV), and C(HCV) are most common, with HBV being the most widespread worldwide. Both HBV and HCV contribute substantially to global morbidity and mortality. However, HBV accounts for the most significant burden of chronic infections and associated complications, including cirrhosis and hepatocellular carcinoma (HCC). HBV infection is one of the leading causes of HCC globally. The chronically infected individuals face a lifetime risk of up to 25% of developing liver cancer, which progresses from cirrhosis and is affected by many comorbidities. Clinical and epidemiological studies, including research from our group, have shown that alcohol consumption in HBV-infected people speeds up disease progression, increases viral replication, and worsens liver damage. Heavy alcohol use is a major cofactor that significantly raises the risk of HCC in patients with HBV-related cirrhosis. Despite this well-established link, the safe level of alcohol consumption for HBV-infected patients remains unclear. Additionally, other cofactors such as viral co-infections, metabolic disorders, genetic predisposition, demographic factors, and environmental exposures interact with alcohol to influence HBV-related disease outcomes. Understanding the systemic effects of alcohol and its underlying mechanisms in HBV development is essential to defining its role as a comorbid factor in liver disease progression. This brief review highlights current knowledge and mechanistic insights into how alcohol influences HBV infection, contributes to HCC development, and acts as a comorbid factor that worsens disease severity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.